Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06156800
Other study ID # RT-NOW
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date May 1, 2024
Est. completion date February 1, 2026

Study information

Verified date February 2024
Source Lawson Health Research Institute
Contact David Palma, MD
Phone 519-685-8650
Email David.Palma@lhsc.on.ca
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

When a doctor suspects cancer, often a biopsy is taken for testing to confirm if cancer is present. Usually, doctors would wait for the results of a biopsy before delivering radiation, but this may lead to a patient having to wait for a treatment that he or she urgently needs. With long wait times for biopsies in Canada, this may lead to symptoms and risks of complications from cancer in the meantime. Therefore, this study is being done to answer the following question: Is it safe and feasible to deliver radiation before obtaining a biopsy in a carefully selected group of patients who urgently need radiation treatment.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 48
Est. completion date February 1, 2026
Est. primary completion date May 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age 18 years or older - Willing to provide informed consent - Palliative treatment intent: either metastatic or incurable locally advanced disease - Tissue diagnosis is not required for determination of dose/fractionation scheme - Recent cross-sectional imaging [for example - Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography/Computed Tomography (PET/CT)] of the area to be treated, done within the past 3 months - Treating physician considers the pre-test probability of cancer greater than 95 percent based on clinical judgement and radiological findings. - The patient has at least 1 site of cancer amenable to biopsy - As per standard practices, if the radiation oncologist will be radiating the only site available to biopsy, they should proceed with caution. Participants should only be enrolled on trial if the risk of harm from delaying Radiation Therapy (RT) significantly outweighs the risks of possible non-diagnostic tissue. If the participant may potentially be eligible for systemic therapy, the treating radiation oncologist should consult a medical oncologist for an opinion regarding the risks of non-diagnostic molecular testing. The weighing of these priorities should be thoroughly discussed with the participant and the discussion should be documented. - Reasons for radiating a participant with a single lesion prior to biopsy include: - Spinal cord compression (actual or impending) and inoperable - Brain metastasis with significant symptoms or neurologic deficits and inoperable - Other lesions causing neurologic deficit - Pulmonary lesion causing or threatening lung obstruction - Uncontrolled bleeding (including hemoptysis and hematuria) - Superior vena cava obstruction (actual or impending) - Limited upside to molecular testing, as determined by the medical oncologist (for example - participant unfit for available systemic therapies, limited options for systemic therapy) - Radiation is considered urgent (for example - participant should receive radiation prior to biopsy date) o Urgent indications may include but are not limited to the reasons listed previously, as well as the following: - Painful metastases or primary lesion not adequately responding to analgesia - Symptomatic brain metastases - Bleeding - Impending pathologic fracture Exclusion Criteria: - Participant is potentially eligible for curative treatment - Clinical suspicion of lymphoma o Some features may be suggestive of lymphoma, including fever or night sweats (for example - B symptoms excluding weight loss), or imaging showing well-defined, homogenous lymphadenopathy. These findings are not exclusion criteria specifically, but should be considered by the clinician in formulating their differential diagnosis.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Canada London Regional Cancer Program, London Health Sciences Centre London Ontario

Sponsors (1)

Lead Sponsor Collaborator
David Palma

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent of Inappropriate Use of Radiation Therapy in Participants with Urgent Indications Treated Prior to Biopsy Results The percentage of participants in whom management would have differed, based on the final pathology, if the pathology had been known prior to radiation therapy.
Inappropriate use of radiation therapy is defined as:
If a non-cancerous process was treated, Or, the use of radiation therapy was inappropriate in hindsight (for example, the participant would have clearly been better treated with alternative options).
2 weeks after biopsy results
Secondary Histological Diagnostic Accuracy Histological diagnostic accuracy is defined as the percentage of biopsies that yielded a histological diagnosis. This will include a comparison of diagnostic yield between biopsies done at radiated vs. non-radiated sites. 2 weeks after biopsy results
Secondary Molecular Testing Accuracy Molecular testing accuracy is defined as the percentage of biopsies that yielded enough viable tissue for molecular testing/diagnosis. 2 weeks after biopsy results
Secondary Number of Biopsy Attempts Required 2 weeks after biopsy
Secondary Biopsy Complication Rates 2 weeks after biopsy
Secondary Time from Enrollment to First Fraction of Radiation Therapy Within 1 year after enrollment
Secondary Time from Enrollment to Biopsy Within 1 year after enrollment
Secondary Evidence of Radiation Effect in Biopsy 2 weeks after biopsy results
Secondary Overall Survival 1 year after enrollment
Secondary Edmonton Symptom Assessment System Revised Scores Participants will rate their symptoms on a scale of 1 to 10, 0 being the best and 10 being the worst.
Examples of symptoms included in the Edmonton Symptom Assessment System revised are pain, tiredness, nausea, appetite, depression, and so on.
2 weeks after radiation therapy of 2 weeks after biopsy
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients